Matthew Wongchenko

Matthew Wongchenko is a Principal Scientific Manager at Genentech, specializing in oncology drug development. With a background in cancer signaling and biomarker development, they have contributed to significant projects, including the regulatory approval of key treatment combinations in melanoma. Previously, Matthew held positions at OSI Pharmaceuticals and ARIAD Pharmaceuticals, where they advanced small molecule inhibitors and conducted translational studies on multi-targeted kinase inhibitors. Their expertise also extends to developing commercial diagnostic strategies and leading scientific collaborations in clinical research settings.